Published in
Elsevier, Clinical Colorectal Cancer, 4(20), p. 314-317, 2021
DOI: 10.1016/j.clcc.2021.07.001
Links
Tools
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients
Journal article published in 2021 by
Roberto Moretto,
Daniele Rossini,
Iolanda Capone 
,
Alessandra Boccaccino ,
Federica Perrone,
Elena Tamborini,
Gianluca Masi ,
Carlotta Antoniotti,
Federica Marmorino,
Veronica Conca ,
Beatrice Borelli,
Angelo Martignetti,
Irene Pecora,
Francesca Simionato,
Samanta Cupini
and other authors.
,
Alessandra Boccaccino ,
Federica Perrone,
Elena Tamborini,
Gianluca Masi ,
Carlotta Antoniotti,
Federica Marmorino,
Veronica Conca ,
Beatrice Borelli,
Angelo Martignetti,
Irene Pecora,
Francesca Simionato,
Samanta Cupini
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 